Background: Anti-Sclerostin antibody (Scl-Ab) is a promising new bone anabolic therapy. Although anti-Scl-Ab stimulates bone formation and repair in the appendicular and axial skeleton, its efficacy in the craniofacial skeleton is still poorly understood.
| I NT ROD UCTI ON
Advances in the study of bone remodeling have led to the development of a monoclonal antibody therapy designed to stimulate osteoblastic activity. This anti-Sclerostin antibody (Scl-Ab) has emerged as a reliable and robust osteoanabolic therapy for bone diseases with a deficiency in bone formation. [1] [2] [3] The Scl-Ab binds and inhibits sclerostin, a glycoprotein expressed by bone-embedded osteocytes. 4, 5 Sclerostin is a potent inhibitor of the osteogenic Wnt pathway. 6 Sclerostin was identified by studying the loss-of-function mutation in patients with the rare genetic disorder Sclerosteosis. 1, 4, 5, 7 Sclerosteosis is characterized by extremely high bone mass throughout the skeleton, tall stature, and enlarged jaws. [8] [9] [10] [11] Targeted inhibition of Sclerostin using Scl-Ab has several therapeutic applications. By stimulating bone formation and suppressing bone resorption, 8 Scl-Ab increases axial bone formation, density, and strength. The Scl-Ab also significantly improves bone repair in a number of animal models. 5, [12] [13] [14] Clinical studies with Scl-Ab have shown dramatic improvements in bone mineral density at the spine and hip in men and women with osteoporosis. 15, 16 Furthermore, Sclerostin is induced by inflammation and promotes inflammatory bone loss, which makes Scl-Abs an attractive therapeutic option for mandibular pathologies characterized by inflammation and reduced bone formation, such as periodontitis and mandibular osteoradionecrosis (ORN). 17 However, there is limited data on the effect of Scl-Ab on the craniofacial skeleton. Two previous studies have shown anabolic effects of Scl-Ab in maxillary alveolar bone in the setting of periodontitis but there is no previous description of the Scl-Ab effect on the mandibular bone. 2, 18 Patients with Down syndrome have low bone mass with reduced osteoblast activity and bone turnover. 19 Craniofacial analyses of humans with Down syndrome reveal several skeletal abnormalities, including small atrophic mandibles with significantly reduced alveolar height. 20 Murine models of Down syndrome exhibit reduced bone volume and trabecular thickness in the axial skeleton, although no studies have evaluated the mandibular bone. 21 One of the most studied mouse models of Down syndrome is the Ts65Dn (Ts65) mouse. 22, 23 The Ts65 mouse strain is a Down syndrome model characterized by segmental trisomy for the region of mouse chromosome 16 that contains approximately 75% of the human chromosome 21-homologous genes. 22 The low bone mass phenotype of Ts65Dn mice is due to cell-intrinsic defects in osteoblast differentiation, which leads to a reduction in bone formation. In addition, osteoclast-mediated bone resorption is also reduced but not enough to overcome the low bone formation rate. 21 The Ts65Dn mouse is the most widely used and accepted model of trisomy 21 in mice. These animals display many of the cognitive and behavioral phenotypes of patients with Down syndrome as well as the skeletal, craniofacial, and cardiovascular and megakaryocytopoiesis that characterizes people with Down syndrome. Other murine models do exist, however, Ts65Dn provides the strongest low bone mass phenotype of all the Down syndrome murine models. 24, 25 Because the analysis of the Ts65 skeletal phenotype focused on the axial skeleton, the extent to which this mouse model recapitulates the mandibular atrophy observed in human Down syndrome remains to be determined. An osteoanabolic therapy that could increase the mandibular alveolar bone and enhance mandibular bone repair could be highly beneficial for Down syndrome and other conditions. The mandibular bone is particularly susceptible to inflammatory bone loss, which has historically been a very difficult problem to treat. [26] [27] [28] Antiresorptive bisphosphonates are the most common therapy used to treat bone loss in the axial skeleton. However, they provide little benefit to the mandibular bone and, in some cases, can be harmful and lead to bisphosphonate-related osteonecrosis of the jaw. 29 Only male mice were evaluated due to the decreased fertility of Ts65 male mice and the necessity of Ts65 female mice for colony maintenance. Animals were purchased at 6 weeks and aged as required. Twenty 8-week-old male mice were used in this study. However, 1 mouse in the Ts65 group died independently of treatment, leaving 19 (10 wild type and 9 Ts65) mice for final analysis. Vehicle (0.9% saline) or Scl-Ab (monoclonal Scl-AbVI; Novartis, Switzerland) was administered i.v. at 100 mg/kg, weekly for 3 weeks. Five wild type and 4 Ts65 mice were treated with Scl-Ab. The dose was chosen based on efficacy in previous studies and on supplier recommendations. All mice were euthanized 8 days after the last injection and the right and left hemimandibles were harvested.
| Radiologic analysis
All right hemimandibles were first fixed in 10% neutralized buffered formalin overnight and then stored in 70% ethanol for microcomputed X-ray tomography (micro-CT). The micro-CT was performed using a Scanco lCT 50 highresolution specimen scanner (Scanco Medical AG, Bassersdorf, Switzerland). After identification of the hemimandible on a scout view radiograph, images were acquired at an isotropic resolution of 10 lm in all 3 dimensions. Additional scan settings included an integration time of 500 ms, an X-ray beam potential of 55kVp, and a beam intensity of 109lA. For each 1808 of imaging, 1000 projections were acquired. After scanning, 3D microstructural image data were reconstructed using the Scanco cone-beam reconstruction algorithm. Structural and density calibration of the scanner is performed regularly using a calibration phantom provided by the manufacturer.
Volumetric measurements were carried out after the selection of a standardized region of interest, which was composed of the alveolar bone surrounding the roots of molars M1, M2, and M3. The length of the region of interest extended from the most mesial aspect of the M1 root to the most distal aspect of the M3 root. The width of the region of interest extended from the most buccal aspect of any root of the molars to the most palatal aspect of any root. The height of the region of interest extended from the inferior most aspect of any root to the alveolar bone crest (ABC). The abovementioned region of interest defined the border for volumetric analysis on 2D parasagittal images by a single blinded investigator who drew the contour of the desired alveolar bone region so as to maximize the quantification of bone and minimize the inclusion of roots ( Figure 1A ). Bone volume per total volume, trabecular thickness, trabecular number, and trabecular spacing were then calculated from each specimen. 31 Similar to the method described by Chen et al, 2 linear measurements of the distance between the cemento-enamel junction (CEJ) and the ABC were done to assess the length of exposed tooth and the height of the alveolar bone. The greater the measured distance, the more of the tooth was exposed and the alveolar crest height shorter was shorter. This linear measurement for each specimen was taken at the mesial surface of M1, in the plane where the distal root of M1 was the longest in sagittal sections of micro-CT scans ( Figure 1B ,C).
| Histologic analysis
All left hemimandibles were fixed in formalin overnight and then decalcified in 10% EDTA (pH 7.4) for 14 days. Paraffin embedding and sectioning was performed by the Gladstone Translational Pathology Core Laboratory. Sagittal sections (7 lm) of the left hemimandibles were stained with hematoxylin-eosin and viewed for qualitative histologic analysis using camera-assisted light microscopy (Nikon Labophot-2; Nikon, Tokyo, Japan). The cancellous alveolar bone between the anterior and middle molar roots was used as a standardized area for evaluation (see Figure 2 ). bone using micro-CT of wild-type mice treated with vehicle or Scl-Ab for 3 weeks. Volumetric analysis of a defined mandibular region of interest ( Figure 1A ) demonstrated that wild-type mice treated with Scl-Ab had higher average mandibular bone volume (bone volume per total volume) than vehicle-treated wild-type mice ( Figure 2 , Table 1 ). The Scl-Ab also increased the trabecular thickness of alveolar bone, a clinically relevant measure of bone quality that relates to tooth retention. 32 One of the most critical measures of overall mandibular bone health is the height of the ABC. The height of the bone crest is a hallmark of mandibular bone health in several diseases, including ORN, periodontitis, and Down syndrome, all of which have reduced bone crest heights in humans. 2, 33, 34 To measure the height of the ABC, standard landmarks were used to identify the plane for measurement of the linear distance between the mandibular CEJ and alveolar bone crest (CEJ-ABC distance) for each specimen ( Figure 1B,C) . The longer the linear distance, the shorter the bone crests. Relative to vehicle-treated wildtype mice, Scl-Ab treatment significantly decreased the average CEJ-ABC distance ( Figure 1B ,C, Figure 3 , Table  1 ). Therefore, consistent with the anabolic effects of the Scl-Ab on the axial and appendicular skeleton, Scl-Ab also promotes the anabolism of mandibular bone in multiple clinically relevant outcomes. Reconstructions of micro-CT scans support the quantitative increase in alveolar bone in specimens treated with Scl-Ab compared with controls (see Figure 4 ).
| Skeletal phenotype in Down syndrome also affects mandibular bone
Although Ts65 mice have low bone mass in the appendicular and axial skeleton, whether or not the Ts65 mice also recapitulate the human Down syndrome craniofacial bone phenotype is unknown. Using the same micro-CT-based measures as above, we found that Ts65DN mice had reduced bone volume (bone volume per total volume) and trabecular thickness, and an increased average CEJ-ABC distance compared with wild-type mice (Figures 2 and 3 , Table 1 ). Therefore, the low bone mass phenotype of Ts65 Down syndrome mice extends to the mandible and is consistent with the craniofacial phenotype observed in human Down syndrome. 20 
| Rescue of Down syndrome mandibular skeletal phenotype with sclerostin antibody
Because the Scl-Ab stimulated anabolic bone formation in the mandible, we sought to determine if Scl-Ab could rescue the low bone mass phenotype of Down syndrome mandibular bone in the Ts65 mice. Remarkably, Scl-Ab treatment completely normalized each aspect of the Ts65 mandibular bone phenotype. The bone volume per total volume, trabecular thickness, and CEJ-ABC measures in Scl-Ab-treated Ts65 mice were statistically indistinguishable from the vehicle-treated wild-type controls (Figures 2 and 3 , Table 1 ). Therefore, Scl-Ab exerts an anabolic effect on Down syndrome mandibular bone, rescuing it to wild-type levels according to several clinically relevant outcomes.
| Histologic analysis of alveolar bone
To determine if the newly formed bone was morphologically normal, the alveolar bone in this region of interest was evaluated histologically for all specimens. Similar to the results of micro-CT analysis, Scl-Ab-treated specimens had qualitatively more alveolar bone in between the roots of M1 and M2; whereas Ts65 Down syndrome mice seemed to have reduced amounts of bone. This seemed to normalize with Scl-Ab therapy (see Figure 5 ). We evaluated several other features of the alveolar bone, including collagen and canalicular organization but observed no differences (data not shown). Thus, our histological evaluation revealed that the bone in all specimens was well organized and histologically normal in each outcome that we examined.
| DI S CU S S IO N
The current study is the first report on the effects of Scl-Ab on mandibular alveolar bone, on either wild-type mice or in the context of Down syndrome. The osteoanabolic effects of Scl-Ab were significant in both groups. Diseases that compromise mandibular bone cause a loss of bone at the alveolar ridge, predisposing the mandible for tooth loss or poor integration of dental implants. The CEJ and ABC are established measures of the alveolar ridge and are surrogates for understanding the health of the mandibular bone. The Scl-Ab was not only able to increase the mandibular bone volume, but detailed micro-CT analysis demonstrated that Scl-Ab also increased ABC height. This is the first report of an osteoanabolic agent increasing the wild-type mandibular ABC height and bone volume. This suggests that treatment with Scl-Ab has a wide potential clinical application for mandibular alveolar bone defect diseases, such Down syndrome. Sclerostin inhibits osteoblast activity by antagonizing Wnt signaling. 1, 5 The Scl-Ab has exciting potential as an anabolic bone therapy 5 and is currently in phase III clinical trials for the treatment of osteoporosis. In phase II clinical trials, all dose levels of Scl-Ab significantly increased bone mineral density in the lumbar spine with no increase in adverse events. 15 These trials focused on treatment for osteoporosis and evaluated the bone mineral density of the lumbar spine as the primary endpoint. Although Scl-Ab increases axial bone density, there is limited evidence on the effects of Scl-Ab on the craniofacial skeleton and none specifically on the mandibular bone. Sclerosteosis and Van Buchem disease are 2 rare autosomal recessive syndromes caused by loss of function mutations in the Sclerostin gene. Several craniofacial abnormalities have been described in these patients, including mandibular overgrowth, facial palsy, loss of hearing, delayed tooth eruption, and malocclusion. Patients with Sclerosteosis characteristically have tall stature, with increased cortical density throughout the skeleton. These findings support the idea that Sclerostin is an important regulator of mandibular bone growth and, thus, a potential therapeutic target. 35 With improved medical management, individuals with Down syndrome have a longer life expectancy. Only recently has the low bone mass phenotype in Down syndrome been documented. 21 Individuals with Down syndrome have a reduction in bone accrual during childhood and adolescence, which leads to low bone mass in young adulthood, and later osteoporosis and increased risk of fracture. The low bone mass phenotype of patients with Down syndrome was replicated in Ts65 male mice. Fowler et al 21 found that Ts65 mice had significantly decreased numbers of osteoblasts and osteoclasts on bone surfaces, resulting in decreased bone formation and bone resorption. The balance of osteoblast and osteoclast activity in this low bone turnover state favored bone resorption, which underlies the reduced bone mass in Ts65 mice. Because this low bone mass phenotype is accompanied by abnormally low bone resorption, Ts65 mice are uniquely candidates for osteoanabolic therapy but not antiresorptive bone therapy. In support of this idea, anabolic PTH treatment increased bone mineral density in the axial skeleton of Ts65 mice, 21 and we find that Scl-Ab increases bone formation in the mandible.
The mandibular bone has previously been shown to have unique metabolic properties and discrete responses to pharmacologic, mechanical, and hormonal stimuli. Studies have demonstrated differences in both osteoclastogenic potential and osteoclast numbers of mandibular bone compared to long bone. Specifically, the mandibular bone had fewer osteoclasts in basal conditions and after PTH 11,25D 3 stimulation. Although detailed histomorphometry of the mandible was not performed in this study, the low osteoclast activity of the mandibular bone would be expected to exacerbate the low bone resorption phenotype reported for the long bone of Ts65 mice. 21 These observations, together with those reported here, suggest that the beneficial effects of Scl-Ab on the mandibular bone likely occur by stimulating bone formation, rather than by further suppressing bone resorption. 36, 37 The ability to stimulate new mandibular bone formation would also be highly beneficial for mandibular ORN. In mandibular ORN, both bone mass and bone turnover are reduced. Like Down syndrome, the low bone turnover in mandibular ORN is due to a reduction in osteoblast activity. 38, 39 This dysregulated bone remodeling predisposes the ORN mandible for necrosis and a limited ability to heal after dental extractions. 28, 38 The ORN of the mandible continues to be one of the most devastating complications for patients undergoing treatment for head and neck cancer. Severe bone necrosis causes significant morbidity without any reliable treatment options. Current strategies for treating mandibular ORN focus on hyperbaric oxygen therapy to increase tissue perfusion or inhibiting osteoclast activity with bisphosphonates. 28, 30 Neither method provides a reliable benefit and patients often must undergo major mandibular resections and free tissue transfer reconstruction despite being cancer free. Furthermore, bisphosphonates may actually be harmful in the setting of mandibular inflammation leading to bisphosphonate-related osteonecrosis of the jaw. 26, 29 Thus, an osteoanabolic therapy, such as the Scl-Ab, would be ideal for mandibular ORN treatment, as well as for the treatment of Down syndrome. The encouraging results of this proof of principle study motivate additional research to identify a dose that would be optimal in a clinical context.
| C ONCL US I ON
In conclusion, Scl-Ab treatment was able to create greater alveolar crest height and higher alveolar bone density in both wild-type mice and in a murine model of Down syndrome. Although we did not perform dynamic histomorphometry, prior studies suggest that this response is primarily due to increased bone formation. This novel finding may have several new valuable clinical applications for Scl-Ab in treating mandibular pathologies with reduced bone mass, such as in human Down syndrome and mandibular ORN.
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